Login / Signup

Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison.

Stefano CascinuToshifumi TadaShigeo ShimoseTakashi KumadaTakashi NiizekiStefano CascinuAlessandro Cucchetti
Published in: Targeted oncology (2021)
The present MAIC highlights that the combination of atezolizumab plus bevacizumab is superior to lenvatinib. However, updated data or sub-analyses of the IMbrave150 trial would provide more robust estimates for such a treatment comparison.
Keyphrases
  • clinical trial
  • electronic health record
  • phase iii
  • squamous cell carcinoma
  • big data
  • replacement therapy
  • double blind